BACKGROUND: It was hypothesized that the inflammatory response of patients with severe sepsis may result in changes of plasma levels of oxidized low-density lipoproteins (ox-LDLs) and that drotrecogin alpha (activated) (DAA) (Xigris, Eli Lilly and Company [Indiana 46285, USA]) may influence ox-LDL levels. MATERIALS AND METHODS: The ox-LDL levels were measured in severe septic patients on day 1, 4, and 7 of severe sepsis. Patients were treated either with or without DAA. RESULTS: The ox-LDL levels increased significantly (P < .05) from day 1 to day 7 (day 1, mean +/- SEM, 25.4 +/- 1.8 U/L; day 4, mean +/- SEM, 34.3 +/- 2.1 U/L; day 7, mean +/- SEM, 38.3 +/- 2.1 U/L) in all patients (n = 68). The ox-LDL levels increased significantly from day 1 to day 7 both in patients treated with (n = 31) and without DAA (n = 37) (P < .001) (DAA-group: day 1, mean +/- SEM, 24.4 +/- 2.8 U/L; day 4, mean +/- SEM, 35.5 +/- 2.9 U/L; day 7, mean +/- SEM, 40.7 +/- 3.2 U/L) (control group: day 1, mean +/- SEM, 26.3 +/- 2.8 U/L; day 4, mean +/- SEM, 33.2 +/- 2.9 U/L; day 7, mean +/- SEM, 36.4 +/- 2.9 U/L). No significant differences of ox-LDL levels were observed between both groups at any point of time (P > .05). CONCLUSIONS: The ox-LDL concentrations increase significantly during the first week of severe sepsis and are not affected by administration of drotrecogin alpha (activated) (Xigris).
BACKGROUND: It was hypothesized that the inflammatory response of patients with severe sepsis may result in changes of plasma levels of oxidized low-density lipoproteins (ox-LDLs) and that drotrecogin alpha (activated) (DAA) (Xigris, Eli Lilly and Company [Indiana 46285, USA]) may influence ox-LDL levels. MATERIALS AND METHODS: The ox-LDL levels were measured in severe septicpatients on day 1, 4, and 7 of severe sepsis. Patients were treated either with or without DAA. RESULTS: The ox-LDL levels increased significantly (P < .05) from day 1 to day 7 (day 1, mean +/- SEM, 25.4 +/- 1.8 U/L; day 4, mean +/- SEM, 34.3 +/- 2.1 U/L; day 7, mean +/- SEM, 38.3 +/- 2.1 U/L) in all patients (n = 68). The ox-LDL levels increased significantly from day 1 to day 7 both in patients treated with (n = 31) and without DAA (n = 37) (P < .001) (DAA-group: day 1, mean +/- SEM, 24.4 +/- 2.8 U/L; day 4, mean +/- SEM, 35.5 +/- 2.9 U/L; day 7, mean +/- SEM, 40.7 +/- 3.2 U/L) (control group: day 1, mean +/- SEM, 26.3 +/- 2.8 U/L; day 4, mean +/- SEM, 33.2 +/- 2.9 U/L; day 7, mean +/- SEM, 36.4 +/- 2.9 U/L). No significant differences of ox-LDL levels were observed between both groups at any point of time (P > .05). CONCLUSIONS: The ox-LDL concentrations increase significantly during the first week of severe sepsis and are not affected by administration of drotrecogin alpha (activated) (Xigris).
Authors: František Novak; J Borovska; M Vecka; J Rychlikova; L Vavrova; H Petraskova; A Zak; O Novakova Journal: Lipids Date: 2016-12-30 Impact factor: 1.880
Authors: Michael Behnes; Martina Brueckmann; Siegfried Lang; Christian Putensen; Joachim Saur; Martin Borggrefe; Ursula Hoffmann Journal: BMC Infect Dis Date: 2012-09-14 Impact factor: 3.090
Authors: Pamela R Hall; Bradley O Elmore; Cynthia H Spang; Susan M Alexander; Brett C Manifold-Wheeler; Moriah J Castleman; Seth M Daly; M Michal Peterson; Erin K Sully; Jon K Femling; Michael Otto; Alexander R Horswill; Graham S Timmins; Hattie D Gresham Journal: PLoS Pathog Date: 2013-02-14 Impact factor: 6.823